Dry powder inhalation products developer Pulmatrix has appointed former Civitas Therapeutics CEO Mark Iwicki as chairman of its board of directors, the company said. Iwicki has also previously headed Blend Pharmaceuticals and Sunovion and currently sits on the boards of directors of Kala Pharmaceuticals, Aimmune, Nimbus Therapeutics, Merus and Taris Biomedical.
Iwicki said, “Pulmatrix has demonstrated great innovation in developing inhaled therapies to address pulmonary conditions, and I look forward to working with its board and management to advance this mission.”
Pulmatrix President and CEO Robert Clarke commented, “Mark’s outstanding track record building biopharmaceutical businesses will serve us well as we continue to develop Pulmatrix’s pipeline of drugs for cystic fibrosis, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.”
Pulmatrix, which announced a merger with Ruthigen in March 2015, develops products based on its iSPERSE particle engineering technology.
Read the Pulmatrix press release.
